Ameliorative effect of mepenzolate bromide against pulmonary fibrosiss

Journal of Pharmacology and Experimental Therapeutics

Volumn 350, Issue 1, 2014, Pages 79-88

  Kurotsu, Shota ^a   Tanaka, Ken Ichiro ^a   Niino, Tomomi ^a   Asano, Teita ^a   Sugizaki, Toshifumi ^a   Azuma, Arata ^b   Suzuki, Hidekazu ^c   Mizushima, Tohru ^a  

^a KEIO UNIVERSITY   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; GLUTATHIONE TRANSFERASE; IPRATROPIUM BROMIDE; MEPENZOLATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TIOTROPIUM BROMIDE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL OXYGEN SATURATION; ARTICLE; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; CELL DEATH; CONTROLLED STUDY; DOSE RESPONSE; FORCED VITAL CAPACITY; LEUKOCYTE COUNT; LUNG ALVEOLUS CELL; LUNG COMPLIANCE; LUNG MECHANICS; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BENZILATES; BLEOMYCIN; BRONCHOALVEOLAR LAVAGE FLUID; CELL COUNT; CELL DEATH; GLUTATHIONE TRANSFERASE; HYDROXYPROLINE; INFLAMMATION; LUNG; LUNG COMPLIANCE; MALE; MICE; MYOFIBROBLASTS; NADPH OXIDASE; OXYGEN; PIPERIDINES; PULMONARY FIBROSIS; TRANSFORMING GROWTH FACTOR BETA1; VITAL CAPACITY;

EID: 84903546729     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.213009     Document Type: Article

References (40)

1. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, and Ohi M, et al. (2005) Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171:1040-1047. (Pubitemid 40616955)
2. Barcellos-Hoff MH and Dix TA (1996) Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol 10:1077-1083. (Pubitemid 26299216)
3. Bellocq A, Azoulay E, Marullo S, Flahault A, Fouqueray B, Philippe C, Cadranel J, and Baud L (1999) Reactive oxygen and nitrogen intermediates increase transforming growth factor-beta1 release from human epithelial alveolar cells through two different mechanisms. Am J Respir Cell Mol Biol 21:128-136. (Pubitemid 129508636)
4. Buckley JP, DeFEO JJ, and Reif EC (1957) The comparative antispasmodic activity of N-methyl-3-piperidyl diphenylglycolate methobromide (JB-340) and atropine sulfate. J Am Pharm Assoc Am Pharm Assoc (Baltim) 46:592-594.
5. Chen JY (1959) Antispasmodic activity of JB-340 (N-methyl-3- piperidyldiphenylglycolate methobromide) with special reference to its relative selective action on the sphincter of Oddi, colon and urinary bladder of the dog. Arch Int Pharmacodyn Ther 121:78-84.
6. Chilosi M, Carloni A, Rossi A, and Poletti V (2013) Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema. Transl Res 162:156-173.
7. du Bois RM (2010) Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 9:129-140.
8. Griendling KK, Minieri CA, Ollerenshaw JD, and Alexander RW (1994) Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74:1141-1148. (Pubitemid 24176909)
9. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, and Gabbiani G (2007) The myofibroblast: one function, multiple origins. Am J Pathol 170:1807-1816. (Pubitemid 47339255)
10. Jankowich MD and Rounds SI (2012) Combined pulmonary fibrosis and emphysema syndrome: a review. Chest 141:222-231.
11. Kim DS, Collard HR, and King TE, Jr (2006) Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 3:285-292. (Pubitemid 43845404)
12. Kinnula VL (2008) Redox imbalance and lung fibrosis. Antioxid Redox Signal 10:249-252.
13. Kinnula VL and Myllärniemi M (2008) Oxidant-antioxidant imbalance as a potential contributor to the progression of human pulmonary fibrosis. Antioxid Redox Signal 10:727-738. (Pubitemid 351225901)
14. Long JP and Keasling HH (1954) The comparative anticholinergic activity of a series of derivatives of 3-hydroxy piperidine. J Am Pharm Assoc Am Pharm Assoc (Baltim) 43:616-619.
15. Luppi F, Cerri S, Beghé B, Fabbri LM, and Richeldi L (2004) Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis. Respir Med 98:1035-1044. (Pubitemid 39317932)
16. Maher TM (2010) Pirfenidone in idiopathic pulmonary fibrosis. Drugs Today (Barc) 46:473-482.
17. Maher TM, Wells AU, and Laurent GJ (2007) Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J 30:835-839. (Pubitemid 351194784)
18. Mak JC (2008) Pathogenesis of COPD. Part II. Oxidative-antioxidative imbalance. Int J Tuberc Lung Dis 12:368-374. (Pubitemid 351507247)
19. Mizushima T (2011) Drug discovery and development focusing on existing medicines:drug re-profiling strategy. J Biochem 149:499-505.
20. Moore B, Lawson WE, Oury TD, Sisson TH, Raghavendran K, and Hogaboam CM (2013) Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol 49:167-179.
21. Nadeem A, Raj HG, and Chhabra SK (2005) Increased oxidative stress and altered levels of antioxidants in chronic obstructive pulmonary disease. Inflammation 29:23-32.
22. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Jr, Lancaster L, Sahn SA, and Szwarcberg J, et al. CAPACITY Study Group (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY):two randomised trials. Lancet 377:1760-1769.
23. Papiris SA, Triantafillidou C, Manali ED, Kolilekas L, Baou K, Kagouridis K, and Bouros D (2013) Combined pulmonary fibrosis and emphysema. Expert Rev Respir Med 7:19-31, quiz 32.
24. Pera T, Zuidhof A, Valadas J, Smit M, Schoemaker RG, Gosens R, Maarsingh H, Zaagsma J, and Meurs H (2011) Tiotropium inhibits pulmonary inflammation and remodelling in a guinea pig model of COPD. Eur Respir J 38:789-796.
25. Pieper MP, Chaudhary NI, and Park JE (2007) Acetylcholine-induced proliferation of fibroblasts and myofibroblasts in vitro is inhibited by tiotropium bromide. Life Sci 80:2270-2273. (Pubitemid 46818281)
26. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, and van Weel C, et al.; Global Initiative for Chronic Obstructive Lung Disease (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176:532-555. (Pubitemid 47403272)
27. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, and Lasky JA, et al.; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis (2011) An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788-824.
28. Sheppard D (2006) Transforming growth factor beta: a central modulator of pulmonary and airway inflammation and fibrosis. Proc Am Thorac Soc 3:413-417. (Pubitemid 44033355)
29. Strieter RM and Mehrad B (2009) New mechanisms of pulmonary fibrosis. Chest 136:1364-1370.
30. Takemasa A, Ishii Y, and Fukuda T (2012) A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice. Eur Respir J 40:1475-1482.
31. Tanaka K, Azuma A, Miyazaki Y, Sato K, and Mizushima T (2012a) Effects of lecithinized superoxide dismutase and/or pirfenidone against bleomycin-induced pulmonary fibrosis. Chest 142:1011-1019.
32. Tanaka K, Ishihara T, Azuma A, Kudoh S, Ebina M, Nukiwa T, Sugiyama Y, Tasaka Y, Namba T, and Ishihara T, et al. (2010a) Therapeutic effect of lecithinized superoxide dismutase on bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 298:L348-L360.
33. Tanaka K, Ishihara T, Sugizaki T, Kobayashi D, Yamashita Y, Tahara K, Yamakawa N, Iijima K, Mogushi K, and Tanaka H, et al. (2013) Mepenzolate bromide displays beneficial effects in a mouse model of chronic obstructive pulmonary disease. Nat Commun 4:2686.
34. Tanaka K, Sato K, Aoshiba K, Azuma A, and Mizushima T (2012b) Superiority of PC-SOD to other anti-COPD drugs for elastase-induced emphysema and alteration in lung mechanics and respiratory function in mice. Am J Physiol Lung Cell Mol Physiol 302:L1250-L1261.
35. Tanaka K, Tanaka Y, Miyazaki Y, Namba T, Sato K, Aoshiba K, Azuma A, and Mizushima T (2011) Therapeutic effect of lecithinized superoxide dismutase on pulmonary emphysema. J Pharmacol Exp Ther 338:810-818.
36. Tanaka K, Tanaka Y, Namba T, Azuma A, and Mizushima T (2010b) Heat shock protein 70 protects against bleomycin-induced pulmonary fibrosis in mice. Biochem Pharmacol 80:920-931.
37. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, and Sato A, et al.; Pirfenidone Clinical Study Group in Japan (2010) Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35:821-829.
38. Walter N, Collard HR, and King TE, Jr (2006) Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc 3:330-338. (Pubitemid 43845410)
39. Willis BC and Borok Z (2007) TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 293:L525-L534. (Pubitemid 47358808)
40. Woessner JF, Jr (1961) The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 93:440-447.